Sep 10, 2021 / 03:45PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Great. Thanks, everybody, for joining us for the next session. Very pleased to have Moderna here.
Quickly before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So very pleased to have Stephane Bancel, who's the CEO of Moderna with us. And Stephane, I thought since you just had a big R&D review yesterday, maybe we could start off with some of the highlights from that.
Stephane Bancel - Moderna, Inc. - CEO & Director
Sure. Well, Matt, good morning and -- or good afternoon, and thank you for having us today.
So yes, yesterday, I think we kind of gave an update on our programs. I think there's basically 4 directions that the company is taking, there's 4 priorities on product side. One is to develop a pan-respiratory annual booster vaccine.
Moderna Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 10, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers